ABSTRACT
The challenges facing the pharmaceutical business world over the last decade are no secret to industry analysts or the interested observer. Pipelines are contracting-major pharmaceutical firms averaged less than one new compound per year during 1995 to 2000. The ability to produce new blockbuster drugs appears to be diminishing; only 10% of those compounds eventually reached sales of more than $350 million annually, and a number of blockbusters are now in-licensed rather than produced through internal drug development processes.
